Total GLP-1 ELISA

Kit Calculator

Estimate required kits based on your number of samples.

Samples

Article no.

Sample setup

Add the number of samples you plan to run. Please ensure that each sample has sufficient volume to meet the kit’s per-well requirement.

Controls

Add a corresponding Mercodia control kit. Note: If controls are selected, more than one control kit may be needed depending on the number of assay kits used and the time between runs

The results show the estimated number of assay kits required based on your input and the assay’s DfU. Actual kit usage may vary depending on workflow and run frequency.

Minimal Number of Kits Required:

Total GLP-1 ELISA

(10-1278-01)

Kit format: 1 x 96 wells

Measurement range: 0.9 - 940 pmol/L (2.8 - 2940 pg/mL)

100% specificity to the predominating isoform, GLP-1 (9-36) amide

High sensitivity

Validated according to CLSI/FDA/EMA

Controls available: 10-1287-01

TALK TO A PERSON

Description

Mercodia Total GLP-1 ELISA

The Mercodia Total GLP-1 ELISA provides a chemiluminescent method for the quantitative determination of amidated glucagon-like-peptide-1 (GLP-1) in human plasma and serum samples. The assay has been validated according to CLSI, FDA, and EMA guidelines.

GLP-1, is one of the major incretin hormones produced in the intestinal L-cells. It is secreted as the active forms (7-37)/(7-36) amide but is rapidly cleaved by the enzyme DPP4 forming the metabolites GLP-1 (9-37)/(9-36) amide. Although the two active forms have shown equal biological potency, the majority of circulating GLP-1 in humans is found in the amidated form.

Mercodia GLP-1 (9-36) Amide Control – Low, Medium, High (10-1287-01) is a three-level control for the Mercodia Total GLP-1 ELISA.

Test characteristics

Species

Human

Sample types

Serum and EDTA plasma

Sample volume

25 µL

Assay range

0.9 - 940 pmol/L (2.8 - 2940 pg/mL)

Detection limit

≤0.65 pmol/L

Incubation

2h + 15 min

Detection method

Chemiluminescence

specificity

The following cross-reactions have been tested:

GLP-1 (1-36) amide

88%

GLP-1 (7-36) amide

93%

GLP-1 (9-36) amide

100%

GLP-1 (1-37)

Not detected

GLP-1 (7-37)

Not detected

Glucagon

Not detected

GIP

Not detected

GLP-2

Not detected

Oxyntomodulin

Not detected

Glicentin

Not detected

Miniglucagon

Not detected

MPGF

Not detected

Liraglutide

Not detected

Exenatide

Not detected

Lixisenatide

Not detected

Dulaglutide

0.07%

directions for use Certificate of Analysis

directions for use

LOT. NO.	DOCUMENT
37049	DfU - 10-1278-01 v. 6.0
36671	DfU - 10-1278-01 v. 6.0
35965	DfU - 10-1278-01 v. 6.0
34076	DfU - 10-1278-01 v. 6.0
35491	DfU - 10-1278-01 v. 6.0
35652	DfU - 10-1278-01 v. 6.0

Certificate of Analysis

LOT. NO.	DOCUMENT
37049	CoA - 10-1278-01
36671	CoA - 10-1278-01
35965	CoA - 10-1278-01
35652	CoA - 10-1278-01
35491	CoA - 10-1278-01
34076	CoA - 10-1278-01

SAFETY DATA SHEET

technical notes

For technical notes specific to Mercodia Total GLP-1 ELISA see:
TN34-0154 Sample collection and handling for Mercodia Total GLP-1 ELISA (10-1278-01)

For other technical notes see our Technical Library

references

Stinson, S. E. et al. (2021). Fasting plasma GLP-1 associates with overweight/obesity and cardiometabolic risk factors in children and adolescents. The Journal of Clinical Endocrinology & Metabolism. Read more >

Jepsen, S. L. et al. (2021). Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut-and GLP-1R-dependent manner. Read more >

Vestergaard, E. T. et al. (2021). Acute ketosis inhibits appetite and decreases plasma concentrations of acyl ghrelin in healthy young men. Diabetes, Obesity and Metabolism, 23(8), 1834–1842. Read more >

Grevengoed, T. J. et al. (2021). An abundant biliary fatty acid metabolite derived from dietary omega-3 polyunsaturated fatty acids regulates triglycerides. Journal of Clinical Investigation. Read more >

Docherty, K. F. et al. (2021). The Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients with Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. Circulation, CIRCULATIONAHA.121.054892 Read more >

Meessen, E. C. E. et al. (2021). Parenteral nutrition impairs plasma bile acid and gut hormone responses to mixed meal testing in lean healthy men. Clinical Nutrition, 40(3). Read more >

Rega-Kaun, G. et al. (2020). Roux-en-Y-Bariatric Surgery Reduces Markers of Metabolic Syndrome in Morbidly Obese Patients. Obesity Surgery, 30(2), 391–400 Read more >

Kaya, D. et al. (2019). TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. Cells, 8(10), 1153. Read more >

Seelig, E. et al. (2019). Exercise and the dipeptidyl‐peptidase IV inhibitor sitagliptin do not improve beta‐cell function and glucose homeostasis in long‐lasting type 1 diabetes—A randomised open‐label study. Endocrinology, Diabetes & Metabolism, e00075. Read more >

Grevengoed, T. J. et al. (2019). N-acyl taurines are endogenous lipid messengers that improve glucose homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 116(49), 24770–24778. Read more >

Roberts, G. P. et al. (2018). Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 14(5), 562–568. Read more >